A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder

Trial Profile

A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Vilazodone (Primary) ; Fluoxetine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan; Forest Laboratories
  • Most Recent Events

    • 21 Feb 2018 Planned number of patients changed from 400 to 470.
    • 21 Feb 2018 Planned End Date changed from 1 Jun 2017 to 8 Sep 2018.
    • 21 Feb 2018 Planned primary completion date changed from 1 May 2017 to 8 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top